Bacteriological and clinical studies on cefepime

Yoshihiro Sawae, Kaoru Okada, Toshiyuki Ishimaru, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Yoshiyuki Niho

Research output: Contribution to journalArticle

Abstract

Bacteriological and clinical studies with cefepime (CFPM), a new parenteral cephalosporin antibiotic were performed, yielding the following results. 1. Antimicrobial activity The MICs of CFPM against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 μ/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, 0.05 for Escherichia coli, 0.20 for Klebsiella pneumoniae, 0.39 for Enterobacter spp. and Serratia marcescens, 0. 10 for Proteus spp., 0.78 for Citrobacter freundii, 6.25 for Acinetobacter calcoaceticus and 12.5 for Pseudomonas aeruginosa. Its activity against Gram-positive cocci was less than cefuzonam and cefmenoxime, but against Gram-negative rods, it was more active than ceftazidime, cefotaxime, cefmenoxime and cefuzonam. 2. Clinical efficacy One patient with pneumonia, 2 with purulent meningitis, 1 with sepsis, 1 with perianal abscess and 1 with ankylosing spondylitis were treated with CFPM at a daily dose of 2.0~4.0g for 3-17 days. Clinical response was excellent in 1, good in 1, fair in 1, poor in 2 and unknown in 1 patient. S. aureus, E. faecalis, Streptococcus milleri, Streptococcus mitis were eradicated by CFPM. No adverse reactions and no abnormal changes of laboratory investigations were observed.

Original languageEnglish
Pages (from-to)169-174
Number of pages6
JournalCHEMOTHERAPY
Volume39
DOIs
Publication statusPublished - Jan 1 1991

Fingerprint

Cefmenoxime
Enterococcus faecalis
Staphylococcus aureus
Streptococcus milleri Group
Streptococcus mitis
Acinetobacter calcoaceticus
Citrobacter freundii
Gram-Positive Cocci
Enterobacter
Serratia marcescens
Proteus
Ceftazidime
Cefotaxime
Ankylosing Spondylitis
Klebsiella pneumoniae
Cephalosporins
Cell Size
Meningitis
Abscess
Pseudomonas aeruginosa

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Sawae, Y., Okada, K., Ishimaru, T., Takaki, K., Shimono, N., Misumi, H., & Niho, Y. (1991). Bacteriological and clinical studies on cefepime. CHEMOTHERAPY, 39, 169-174. https://doi.org/10.11250/chemotherapy1953.39.Supplement2_169

Bacteriological and clinical studies on cefepime. / Sawae, Yoshihiro; Okada, Kaoru; Ishimaru, Toshiyuki; Takaki, Koji; Shimono, Nobuyuki; Misumi, Hiroyasu; Niho, Yoshiyuki.

In: CHEMOTHERAPY, Vol. 39, 01.01.1991, p. 169-174.

Research output: Contribution to journalArticle

Sawae, Y, Okada, K, Ishimaru, T, Takaki, K, Shimono, N, Misumi, H & Niho, Y 1991, 'Bacteriological and clinical studies on cefepime', CHEMOTHERAPY, vol. 39, pp. 169-174. https://doi.org/10.11250/chemotherapy1953.39.Supplement2_169
Sawae, Yoshihiro ; Okada, Kaoru ; Ishimaru, Toshiyuki ; Takaki, Koji ; Shimono, Nobuyuki ; Misumi, Hiroyasu ; Niho, Yoshiyuki. / Bacteriological and clinical studies on cefepime. In: CHEMOTHERAPY. 1991 ; Vol. 39. pp. 169-174.
@article{f726fa3ce8fd476fb162dbf0eff6c04f,
title = "Bacteriological and clinical studies on cefepime",
abstract = "Bacteriological and clinical studies with cefepime (CFPM), a new parenteral cephalosporin antibiotic were performed, yielding the following results. 1. Antimicrobial activity The MICs of CFPM against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 μ/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, 0.05 for Escherichia coli, 0.20 for Klebsiella pneumoniae, 0.39 for Enterobacter spp. and Serratia marcescens, 0. 10 for Proteus spp., 0.78 for Citrobacter freundii, 6.25 for Acinetobacter calcoaceticus and 12.5 for Pseudomonas aeruginosa. Its activity against Gram-positive cocci was less than cefuzonam and cefmenoxime, but against Gram-negative rods, it was more active than ceftazidime, cefotaxime, cefmenoxime and cefuzonam. 2. Clinical efficacy One patient with pneumonia, 2 with purulent meningitis, 1 with sepsis, 1 with perianal abscess and 1 with ankylosing spondylitis were treated with CFPM at a daily dose of 2.0~4.0g for 3-17 days. Clinical response was excellent in 1, good in 1, fair in 1, poor in 2 and unknown in 1 patient. S. aureus, E. faecalis, Streptococcus milleri, Streptococcus mitis were eradicated by CFPM. No adverse reactions and no abnormal changes of laboratory investigations were observed.",
author = "Yoshihiro Sawae and Kaoru Okada and Toshiyuki Ishimaru and Koji Takaki and Nobuyuki Shimono and Hiroyasu Misumi and Yoshiyuki Niho",
year = "1991",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.39.Supplement2_169",
language = "English",
volume = "39",
pages = "169--174",
journal = "CHEMOTHERAPY",
issn = "0009-3165",

}

TY - JOUR

T1 - Bacteriological and clinical studies on cefepime

AU - Sawae, Yoshihiro

AU - Okada, Kaoru

AU - Ishimaru, Toshiyuki

AU - Takaki, Koji

AU - Shimono, Nobuyuki

AU - Misumi, Hiroyasu

AU - Niho, Yoshiyuki

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Bacteriological and clinical studies with cefepime (CFPM), a new parenteral cephalosporin antibiotic were performed, yielding the following results. 1. Antimicrobial activity The MICs of CFPM against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 μ/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, 0.05 for Escherichia coli, 0.20 for Klebsiella pneumoniae, 0.39 for Enterobacter spp. and Serratia marcescens, 0. 10 for Proteus spp., 0.78 for Citrobacter freundii, 6.25 for Acinetobacter calcoaceticus and 12.5 for Pseudomonas aeruginosa. Its activity against Gram-positive cocci was less than cefuzonam and cefmenoxime, but against Gram-negative rods, it was more active than ceftazidime, cefotaxime, cefmenoxime and cefuzonam. 2. Clinical efficacy One patient with pneumonia, 2 with purulent meningitis, 1 with sepsis, 1 with perianal abscess and 1 with ankylosing spondylitis were treated with CFPM at a daily dose of 2.0~4.0g for 3-17 days. Clinical response was excellent in 1, good in 1, fair in 1, poor in 2 and unknown in 1 patient. S. aureus, E. faecalis, Streptococcus milleri, Streptococcus mitis were eradicated by CFPM. No adverse reactions and no abnormal changes of laboratory investigations were observed.

AB - Bacteriological and clinical studies with cefepime (CFPM), a new parenteral cephalosporin antibiotic were performed, yielding the following results. 1. Antimicrobial activity The MICs of CFPM against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 μ/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, 0.05 for Escherichia coli, 0.20 for Klebsiella pneumoniae, 0.39 for Enterobacter spp. and Serratia marcescens, 0. 10 for Proteus spp., 0.78 for Citrobacter freundii, 6.25 for Acinetobacter calcoaceticus and 12.5 for Pseudomonas aeruginosa. Its activity against Gram-positive cocci was less than cefuzonam and cefmenoxime, but against Gram-negative rods, it was more active than ceftazidime, cefotaxime, cefmenoxime and cefuzonam. 2. Clinical efficacy One patient with pneumonia, 2 with purulent meningitis, 1 with sepsis, 1 with perianal abscess and 1 with ankylosing spondylitis were treated with CFPM at a daily dose of 2.0~4.0g for 3-17 days. Clinical response was excellent in 1, good in 1, fair in 1, poor in 2 and unknown in 1 patient. S. aureus, E. faecalis, Streptococcus milleri, Streptococcus mitis were eradicated by CFPM. No adverse reactions and no abnormal changes of laboratory investigations were observed.

UR - http://www.scopus.com/inward/record.url?scp=0025864176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025864176&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.39.Supplement2_169

DO - 10.11250/chemotherapy1953.39.Supplement2_169

M3 - Article

VL - 39

SP - 169

EP - 174

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -